CytomX Therapeutics, Inc. (CTMX) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of CytomX Therapeutics, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTMX
CytomX Therapeutics, Inc.
$2.58HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
MNPR
Monopar Therapeutics Inc.
$81.50HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — CTMX vs MNPR
growth of $100 · dividends reinvested · last 7yCTMX -67.6% (-14.9%/yr)MNPR -40.9% (-7.2%/yr)MNPR compounded faster over this window
CTMX MNPR
CTMX vs MNPR: by the numbers
- •CTMX is the larger company ($561M vs $546M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -435.21% net margin).
Metrics side by side
Valuation
| Metric | CTMX | MNPR |
|---|---|---|
| P/S ratio | 30.65 | N/A |
| P/B ratio | 1.86 | 4.17 |
Profitability
| Metric | CTMX | MNPR |
|---|---|---|
| Gross margin | 98.63% | 0.00% |
| Operating margin | -29.35% | 0.00% |
| Net margin | -435.21% | 0.00% |
| ROE | -26.37% | -13.64% |
| ROIC | -25.42% | -16.89% |
Growth (annualized)
| Metric | CTMX | MNPR |
|---|---|---|
| Revenue CAGR (5Y) | 2.18% | N/A |
| Total return CAGR (5Y) | -12.01% | 27.38% |
Frequently asked
- How have CTMX and MNPR total returns compared?
- Over the past 5 years, CTMX delivered -12.01% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.